Full-Time

Account Specialist

Anti-Infectives

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$78.5k - $192.5k/yr

+ Short-term incentive program

Minneapolis, MN, USA

Remote

Field-based role; candidates should live within a reasonable distance of Minneapolis and travel adequately to cover the territory.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A bachelor's degree in health, sciences, pharmacy, or a business-related field is preferred, or relevant equivalent industry experience is required in lieu of a bachelor's degree; equivalent experience must include at least five years of experience, with three or more years in the pharmaceutical, health, or science industry preferred, and a high school diploma or GED is required.
  • Account-based selling experience with hospitals, wound care centers, or infusion centers, including experience building hospital advocacy for acute products, with or without a formulary win.
  • Experience navigating matrix environments within accounts and complex customers such as integrated delivery networks, academic institutions, hospitals, and outpatient accounts.
  • Knowledge of the formulary approval process and experience driving formulary approvals.
  • A documented history of strong sales performance and advanced sales skills, including communicating novel or complex products and processes, overcoming customer concerns, advancing sales, and gaining new business.
  • Strong business acumen, individual accountability, and ownership of a sales geography, with the ability to multitask, solve problems, influence without authority, prioritize multiple accounts, and analyze diverse data sets using multiple tools to define account and program strategies.
  • Strong planning and organization, presentation and facilitation, learning procedural, technical, and clinical information quickly, presenting complex scientific information to varied audiences, and resolving problems.
  • The ability to cover the assigned geography, travel adequately to cover the territory, and attend scheduled overnight training events and sales meetings.
  • A valid driver's license, ability to pass pre-employment drug screening, and ability to meet safe-driving requirements.
  • Ability to drive a personal or company vehicle or powered material-handling equipment.
  • Ability to satisfy and maintain applicable healthcare industry representative credentialing requirements, including potential background checks, drug screens, immunization or vaccination proof, fingerprinting, and state- or city-specific licenses.
  • Eligibility to work in the United States.
Responsibilities
  • Maximize opportunities for the product portfolio within the assigned geography to increase patient access, develop new business, expand current business, use resources effectively, and achieve geography sales goals.
  • Develop and maintain strategic business relationships with hospitals, integrated delivery networks, academic institutions, outpatient accounts, long-term care facilities, government accounts, and specialty private practices.
  • Advance hospital and specialty customers along the sales continuum and gain prescriber commitments through effective questioning, active listening, and approved data and resources.
  • Deliver on-label presentations and sales calls that highlight product benefits and risks, create awareness of product solutions, and address therapeutic-area gaps.
  • Develop professional relationships and differentiate the Anti-Infective portfolio's value proposition among executives, physicians, hospital staff, and support personnel.
  • Problem-solve product and patient flow through specialty pharmacy, specialty distribution, and buy-and-bill channels.
  • Coordinate and mobilize stakeholders across departments with competing goals to align them on patient-focused solutions.
  • Partner with field medical science liaisons, the National Director of Accounts, Key Account Directors, and in-house teams to identify, design, and adapt appropriate approaches and tactics.
  • Create, develop, execute, and monitor strategic geography business plans, determining account department, channel, healthcare professional focus, and contact frequency.
  • Source, interpret, and use account-level data to maintain account profiles and relationship maps, target key stakeholders and decision-makers, and expand physician usage and the customer base.
  • Attend and participate in local boards, societies, conventions, and healthcare professional meetings; represent AbbVie and assigned products, build relationships, and communicate relevant information internally using on-label communications.
  • Complete required training and comply with company policies and Office of Ethics and Compliance/legal procedures.
  • Collaborate across healthcare-institution departments and organizations to develop account processes and compliant communication strategies.
  • Meet healthcare industry representative credentialing requirements to gain and maintain entry into assigned facilities and organizations.
Desired Qualifications
  • Three or more years of experience in the pharmaceutical, health, or science industry.
  • Experience with buy-and-bill and specialty pharmacy products.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
  • AbbVie raised 2026 guidance to $13.87-$14.07 after broad strength across immunology and neuroscience.
  • Rinvoq and Skyrizi both grew above 23% operationally, showing durable post-Humira momentum.

What critics are saying

  • Humira sales fell 36.1% in Q2 2026; biosimilars keep compressing cash flows.
  • Imbruvica dropped 29.4% in Q2 2026, exposing oncology weakness and IRA pricing damage.
  • Apogee dilutes adjusted EPS through 2027; if Skyrizi stalls, AbbVie loses its bridge.

What makes AbbVie unique

  • Skyrizi and Rinvoq delivered $8.0 billion in Q2 2026, replacing Humira.
  • AbbVie completed Apogee on September 3, 2026, adding long-acting immunology assets.
  • Etentamig posted 74% response in Phase 3 multiple myeloma, broadening oncology optionality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 10th, 2026
AbbVie shifts focus from declining Humira to $8B Skyrizi and Rinvoq growth engines

AbbVie has dramatically shifted its focus away from Humira, its once-flagship drug now facing biosimilar competition. On the company's July 2026 earnings call, Humira received just one sentence, noting global sales of $706 million, down 36.1% operationally but in line with expectations. This marks a stark change from previous quarters when management detailed the reasons behind Humira's decline, including biosimilar competition and molecule compression in the US market. AbbVie now emphasises growth drivers instead. Skyrizi generated $5.5 billion in Q2 2026, whilst Rinvoq exceeded $2.5 billion, both growing above 20% operationally. The company also acquired Apogee Therapeutics in September 2026. Despite the reduced attention, Humira still contributes approximately 4% of AbbVie's quarterly revenue of nearly $17 billion, though management no longer publicly projects its ultimate decline trajectory.

Yahoo Finance
Sep 9th, 2026
Billionaire hedge fund manager doubles down on AbbVie and Costco dividend stocks

Israel Englander's Millennium Management more than doubled its stakes in AbbVie and Costco during the second quarter. AbbVie's revenue grew 10.2% year-over-year to $17 billion in Q2, driven by immunology drugs Skyrizi and Rinvoq. The company recently acquired Apogee Therapeutics for $10.9 billion in cash and is developing ABBV-295, a monthly weight-loss treatment. AbbVie is a Dividend King with over 50 consecutive years of payout increases. Costco's Q3 fiscal 2026 revenue rose 11.6% to $70.5 billion, with comparable sales up 9.8%. The company has raised dividends for 22 consecutive years. However, Costco shares are down 4% over the past year whilst trading at 40.8 times forward earnings, above the consumer staples average of 21.6 times. Both companies maintain strong fundamentals despite different market challenges.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

INSURASALES
Sep 5th, 2026
Manufacturers Life Insurance buys $655M stake in AbbVie as institutions boost pharma holdings

The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.

PharmTech
Sep 4th, 2026
AAPS PharmSci 360: CMC strategies, part 1.

AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.